FDA: Prolia Use in Dialysis Patients May Cause Severe Hypocalcemia
According to a long-term safety study and a separate FDA internal study, Prolia had an increased risk of hypocalcemia in patients with advanced kidney disease on dialysis.
According to a long-term safety study and a separate FDA internal study, Prolia had an increased risk of hypocalcemia in patients with advanced kidney disease on dialysis.
Decrease in bone mass is common in the first 6 to 12 months after kidney transplantation.
Study confirms the care gap in bone health management and fracture prevention among older men with prostate cancer receiving androgen deprivation therapy.
Adjusted odds ratio for type 2 diabetes further reduced for those with more than 8 years of alendronate use
The medication inhibits bone resorption but is associated with prolonged elevation in PTH levels that require treatment.
Study authors identified whether the hemoglobin A1c threshold level where reduction in bone turnover begins.